Dynamic Technology Lab Private Ltd purchased a new position in shares of Bioverativ Inc (NASDAQ:BIVV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,281 shares of the biotechnology company’s stock, valued at approximately $759,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Hikari Power Ltd acquired a new stake in Bioverativ during the 3rd quarter worth about $628,000. Macquarie Group Ltd. acquired a new stake in Bioverativ during the 3rd quarter worth about $18,577,000. Ameriprise Financial Inc. acquired a new stake in Bioverativ during the 3rd quarter worth about $26,496,000. 361 Capital LLC acquired a new stake in Bioverativ during the 3rd quarter worth about $1,553,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Bioverativ during the 3rd quarter valued at about $327,000. 96.95% of the stock is currently owned by institutional investors.

WARNING: “Dynamic Technology Lab Private Ltd Purchases New Stake in Bioverativ Inc (BIVV)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/dynamic-technology-lab-private-ltd-purchases-new-stake-in-bioverativ-inc-bivv/1722984.html.

A number of equities research analysts have recently commented on BIVV shares. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Cowen Inc restated a “buy” rating and set a $80.00 target price on shares of Bioverativ in a research report on Friday, August 4th. Royal Bank Of Canada started coverage on Bioverativ in a research report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 target price on the stock. Evercore ISI started coverage on Bioverativ in a research report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price on the stock. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $71.00 target price on shares of Bioverativ in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $60.93.

Bioverativ Inc (BIVV) opened at $50.24 on Friday. Bioverativ Inc has a 12 month low of $40.00 and a 12 month high of $64.41.

Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.25. The firm had revenue of $291.60 million for the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. Bioverativ’s quarterly revenue was up 27.2% compared to the same quarter last year. equities research analysts expect that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.